You are here

P&T March 2011

Features

In a retrospective study, patients needed one more oxycodone CR tablet per day compared with oxymorphone ER tablets to relieve pain. The authors suggest that switching patients from the highest oxycodone CR strength to the equivalent highest oxymorphone ER strength could generate significant savings in wholesale acquisition costs.

Opinion & Analysis
Past and Present Challenges for the FDA